ONC201是一种具有双重作用机制的口服小分子药物,主要用于治疗携带H3K27M突变的胶质瘤患者。其用法用量需根据患者的年龄和体重进行调整,以实现个性化治疗。 1、在临床前研究中,ONC201的剂量被划分为五个不同的水平(DL),从DL1到DL5,具体剂量如下: DL1: 125mg,每3周给药一次 DL2: 250mg,每3周给药一次 DL3:...
ONC201具有双重作用机制,主要包括作为多巴胺受体D2(DRD2)的拮抗剂和酪蛋白溶解蛋白酶(ClpP)的激动剂。这两种作用机制在抑制肿瘤细胞生长和增殖的同时,也可能对正常细胞或生理功能产生一定影响,引发药物副作用。 1.头痛 头痛是使用ONC201过程中最常见的副作用之一,其程度可从轻微不适到持续性剧烈头痛不等。对于出现严...
参考资料: [1] Oncoceutics Hopes to Develop the First Effective Drug for High-Grade Glioma by Blocking Dopamine from Feeding the Deadly Cancer’s Growth. Retrieved October 25, 2019, from https://wxpress.wuxiapptec.com/oncoceutics-hopes-to-develop-the-first-effective-drug-for-high-grade-gli...
[2]https://www.biospace.com/article/chimerix-s-drug-candidate-improves-survival-for-patients-with-incurable-brain-tumor/ 由于微信推送机制变化,为了不错过我们的内容,请顺手点亮右下方的点赞和在看图标。谢谢您的支持! 编者按: 如果您希...
TIC10 (ONC201) TIC10 (ONC201) inactivates Akt and ERK to induce TNF-related apoptosis-inducing ligand (TRAIL) through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability and improved pharmacokinetics. Phase 1/2. ...
上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。 TIC10(Synonyms: ONC-201)纯度: 99.80% TIC10 (ONC-201) 是一种有效,有口服活性,稳定的肿瘤坏死因子相关的凋亡诱导配体TRAIL诱导剂,其通过抑制Akt和ERK起作用,...
A total of 4 SAEs were reported, none of which were related to the study drug. The most common AEs (regardless of relatedness) included headache, facial nerve disorder, abducens nerve disorder, nausea, fatigue and ataxia. Additional safety data, PK, and clinical outcomes from this arm will ...
The first-in-human clinical trial of ONC201 in advanced aggressive refractory solid tumors confirmed that ONC201 is exceptionally well-tolerated and established the recommended phase II dose of 625 mg administered orally every three weeks defined by drug exposure comparable to efficacious levels in ...
It is also possible that ultimately the immediate drug binding targets may not predict response due to the numerous factors in cells that regulate cell death [31]. Of note, in some studies, DRD2 knockdown or knockout does not impact antitumor efficacy. This could be explained by the ...
在使用ONC201之前,患者应详细阅读药物说明书,并在医生的指导下合理用药。随着药物研发进展和临床应用经验的积累,关于ONC201的用药注意事项也可能会发生变化,患者在接受治疗前应咨询医生以获取最新的用药指导。 免责声明: 以上内容整理于FDA、DRUGS、网络,仅作信息交流之目的,文中观点不代表医伴旅立场,亦不代表医伴旅...